|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ann Thorac Surg 2007;83:1758-1759
© 2007 The Society of Thoracic Surgeons
Division of Cardiothoracic Surgery, University of North Carolina, CB #7065, 3040 Burnett-Womack Building, Chapel Hill, NC 27599-7065
(Email: selzman@med.unc.edu).
| The first 20% of the full text of this article appears below. |
Many patients presenting for cardiac surgery have significant left ventricular hypertrophy, commonly from long-standing hypertension or valvular heart disease. Several groups in the last 5 years have reported that left ventricular hypertrophy predicts excessive rates of morbidity and mortality in patients having cardiac surgery. Left ventricular hypertrophy is troublesome in that myocardial perfusion, particularly to the subendocardium, is not predictably homogenous. This issue becomes even more pertinent with coexisting coronary artery disease. The optimal strategy for protecting hypertrophied hearts, including types of cardioplegia and routes of delivery, remains an active debate both experimentally and clinically.
Wang and colleagues [1] continue their work
Related Article
Ann. Thorac. Surg. 2007 83: 1751-1758.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |